pp 1-15 | Cite as
Multislice PET/CT in Neuroendocrine Tumors
Neuroendocrine tumors (NET) constitute a rare and heterogeneous group of neoplasms with variable clinical and biological features and variable prognosis ranging from very slow growing tumors to highly aggressive ones. Although NET comprise less than 2% of GI malignancies, these tumors are actually increasingly prevalent, which probably mostly reflects higher awareness of these kind of tumors and more sensitive diagnostic tools. Besides clinical features and biochemical tumor markers diagnosis of NETs is based on imaging. Functional PET imaging combined with multi-slice CT (PET/CT) has gained great impact on patient management by optimizing the staging of the disease, visualization of small occult tumor and evaluation of eligibility for somatostatin analogue treatment. This chapter provides an overview on the different radiopharmaceuticals that are used for PET/CT imaging of NETs and their impact on therapeutic management.
- Bombardieri E, Aktolun C, Baum RP et al (2003) FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 30:115–124Google Scholar
- Decristoforo C, Mather SJ, Cholewinski W et al (2000) 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 27:1318–1325CrossRefPubMedGoogle Scholar
- Fottner C, Helisch A, Anlauf M et al (2010) 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab 95:2800–2810CrossRefPubMedGoogle Scholar
- Rindi G, Arnold R, Bosman FT et al (2010) Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman TF, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system, 4th edn. International Agency for Research on cancer (IARC), Lyon, p 13Google Scholar
- Singh S, Asa SL, Dey C et al (2016) Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev 2016; 47: 32–45Google Scholar